‘ΰ
Aaς¨‘ΓΜVWJ
ͺ@jX
ϊ{γΘεwηtka@AaEΰͺεγΣΰΘ
Paradigm sift of the medical care in diabetes
Fumitaka Okajima
Department of Diabetes, Endocrinology and Metabolism, Nippon Medical School Chiba Hokusoh Hospital
Clinical trials have shown that it is difficult to prevent diabetic complications, especially cardiovascular disease (CVD), when classic anti-diabetic drugs are used to control hemoglobin A1c (HbA1c) levels. Trials have also shown that while new anti-diabetic drugs are effective in significantly lowering HbA1c levels, they vary in their ability to prevent CVD complications, with dipeptidyl peptidase-4 (DPP-4) inhibitors failing to prevent CVD and the progression of renal dysfunction, while glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors succeed. However, SGLT2 inhibitors can cause muscle atrophy and dehydration, especially in older patients. In selecting antidiabetics, therefore, physicians should keep such potential effects in mind.
ϊγεγο 2023; 19(1), 32-41
Key words
type 2 diabetes, cardiovascular disease, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, sodium glucose cotransporters 2 inhibitors
Correspondence to
Fumitaka Okajima, Department of Diabetes, Endocrinology and Metabolism, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba 270-1694, Japan
E-mailFokaji@mns.ac.jp
σtF2022N58ϊ@σF2022N1011ϊ |
SΆPDF